1. Home
  2. RAPP
  3. RAPP News

Latest Rapport Therapeutics Inc. Common Stock (RAPP) News on July 12, 2025

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
RAPP

GlobeNewswire

a month ago

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
RAPP

GlobeNewswire

a month ago

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

Rapport Therapeutics to Host 2025 Investor and Analyst Day
RAPP

GlobeNewswire

2 months ago

Rapport Therapeutics to Host 2025 Investor and Analyst Day

Companies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In Growth
RAPP

Simply Wall St.

2 months ago

Companies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In Growth

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
RAPP

GlobeNewswire

2 months ago

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

Rapport Therapeutics to Participate in Upcoming Investor Conferences
RAPP

GlobeNewswire

3 months ago

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
RAPP

GlobeNewswire

4 months ago

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Positive Signs As Multiple Insiders Buy Rapport Therapeutics Stock
RAPP

Simply Wall St.

4 months ago

Positive Signs As Multiple Insiders Buy Rapport Therapeutics Stock

Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares
RAPP

Simply Wall St.

4 months ago

Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
RAPP

GlobeNewswire

4 months ago

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development
RAPP

GlobeNewswire

4 months ago

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Rapport Therapeutics to Participate in Upcoming Investor Conferences
RAPP

GlobeNewswire

5 months ago

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics announces new Phase 1 data for RAP-219
RAPP

TipRanks

6 months ago

Rapport Therapeutics announces new Phase 1 data for RAP-219

RAPP

MT Newswires

6 months ago

Rapport Therapeutics Reports Positive Early Data for Epilepsy Drug Candidate

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
RAPP

GlobeNewswire

6 months ago

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
RAPP

GlobeNewswire

6 months ago

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

We're Not Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn
RAPP

Simply Wall St.

7 months ago

We're Not Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn

RAPP

MT Newswires

7 months ago

Rapport Therapeutics Reports Correlation Between Seizure Biomarker, Clinical Seizures

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
RAPP

GlobeNewswire

7 months ago

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
RAPP

GlobeNewswire

8 months ago

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

Rapport Therapeutics expects cash to fund requirements through 2026
RAPP

TipRanks

8 months ago

Rapport Therapeutics expects cash to fund requirements through 2026

Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
RAPP

GlobeNewswire

8 months ago

Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
RAPP

GlobeNewswire

8 months ago

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
RAPP

GlobeNewswire

10 months ago

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
RAPP

GlobeNewswire

10 months ago

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
RAPP

GlobeNewswire

a year ago

Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update

Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
RAPP

GlobeNewswire

a year ago

Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
RAPP

GlobeNewswire

a year ago

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

Share on Social Networks: